NCT01887886View on ClinicalTrials.gov

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
DRUG

erlotinib

150 mg orally daily

DRUG

onartuzumab

15 mg/kg IV every 3 weeks

DRUG

placebo

IV every 3 weeks

Trial Locations (35)

100

Taipei

11200

Tanjung Bungah

14076

Caen

22927

Großhansdorf

26121

Oldenburg

28007

Madrid

28050

Madrid

28222

Madrid

32803

Orlando

33705

St. Petersburg

33905

Fort Myers

37203

Nashville

40447

Taichung

44718

Canton

44805

Nantes

60637

Chicago

63110

St Louis

69373

Lyon

70006

Metairie

70072

Marrero

78052

Villingen-Schwenningen

90095

Los Angeles

90813

Long Beach

92835

Fullerton

93309

Bakersfield

93454

San Luis Obispo

90095-1772

Los Angeles

791-0280

Ehime

700-8558

Okayama

755-0241

Yamaguchi

501-757

Gwangju

442-723

Suwon

08025

Barcelona

08035

Barcelona

00112

Taipei

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01887886 - A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation | Biotech Hunter | Biotech Hunter